Chan Beals

Direttore Tecnico/Scientifico/R&S presso Abide Therapeutics, Inc.

Health Technology

Finance

Posizioni attive di Chan Beals

Società	Posizione	Inizio	Fine
Abide Therapeutics, Inc. Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.	Direttore Tecnico/Scientifico/R&S	06/01/2016	-

Massachusetts Institute of Technology

Undergraduate Degree

Distribuzione geografica

Stati Uniti

Posizioni

Chief Tech/Sci/R&D Officer	1
Undergraduate Degree	1

Settori

Health Technology	2
Finance	2

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Aziende private	1
Abide Therapeutics, Inc. Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA.	Health Technology

Aziende private

Health Technology